Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone

To assess, in depressed patients, the clinical benefit of mianserin augmentation of fluoxetine or the the benefit of switching treatment from fluoxetine to mianserin. In a 6-week double-blind study we compared the therapeutic efficiency and tolerance of mianserin 60 mg/day (N = 34), mianserin 60 mg/...

Full description

Saved in:
Bibliographic Details
Published in:Acta psychiatrica Scandinavica 2001, Vol.103 (1), p.66-72
Main Authors: FERRERI, M, LAVERGNE, F, BERLIN, I, PAYAN, C, PUECH, A. J
Format: Article
Language:English
Subjects:
Adult
Antidepressive Agents, Second-Generation - pharmacology
Antidepressive Agents, Second-Generation - therapeutic use
Biological and medical sciences
Depressive Disorder, Major - drug therapy
Double-Blind Method
Drug Therapy, Combination
Female
Fluoxetine - pharmacology
Fluoxetine - therapeutic use
Humans
Male
Medical sciences
Mianserin - pharmacology
Mianserin - therapeutic use
Middle Aged
Neuropharmacology
Pharmacology. Drug treatments
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To assess, in depressed patients, the clinical benefit of mianserin augmentation of fluoxetine or the the benefit of switching treatment from fluoxetine to mianserin. In a 6-week double-blind study we compared the therapeutic efficiency and tolerance of mianserin 60 mg/day (N = 34), mianserin 60 mg/day plus fluoxetine 20 mg/day (N = 32) and continuing fluoxetine 20 mg/day (N = 38) in patients with major depression who did not respond to previous fluoxetine treatment. Intent-to-treat analysis showed that at week 6 the decrease in the Hamilton Depression rating scale score was significantly (P < or = 0.03) greater in the mianserin plus fluoxetine group when compared to the fluoxetine group (effect size 0.665). Switching from fluoxetine to mianserin gave intermediate results. Mianserin augmentation of fluoxetine was well tolerated. Mianserin augmentation of fluoxetine in patients non-responders to fluoxetine 20 mg/day increases response to treatment and is well tolerated.
ISSN:0001-690X
1600-0447
DOI:10.1034/j.1600-0447.2001.00148.x